## Pedro Pablo Medina Vico

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6144716/publications.pdf

Version: 2024-02-01

52 papers 3,619 citations

279701 23 h-index 254106 43 g-index

55 all docs 55 docs citations

55 times ranked 6205 citing authors

#	Article	IF	Citations
1	Recurrent splice site mutations affect key diffuse large B-cell lymphoma genes. Blood, 2022, 139, 2406-2410.	0.6	7
2	Opportunities of miRNAs in cancer therapeutics. , 2022, , 153-164.		O
3	PKP1 and MYC create a feedforward loop linking transcription and translation in squamous cell lung cancer. Cellular Oncology (Dordrecht), 2022, 45, 323-332.	2.1	4
4	Multi-omic alterations of the SWI/SNF complex define a clinical subgroup in lung adenocarcinoma. Clinical Epigenetics, 2022, 14, 42.	1.8	5
5	SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade. Nature Communications, 2021, 12, 4319.	5.8	22
6	The SWI/SNF complex regulates the expression of miR-222, a tumor suppressor microRNA in lung adenocarcinoma. Human Molecular Genetics, 2021, 30, 2263-2271.	1.4	2
7	Genome-wide CRISPR interference screen identifies long non-coding RNA loci required for differentiation and pluripotency. PLoS ONE, 2021, 16, e0252848.	1.1	12
8	Plakophilin 1 enhances MYC translation, promoting squamous cell lung cancer. Oncogene, 2020, 39, 5479-5493.	2.6	13
9	The value of desmosomal plaque-related markers to distinguish squamous cell carcinoma and adenocarcinoma of the lung. Upsala Journal of Medical Sciences, 2020, 125, 19-29.	0.4	11
10	LncRNA DLG2-AS1 as a Novel Biomarker in Lung Adenocarcinoma. Cancers, 2020, 12, 2080.	1.7	7
11	Comprehensive Analysis of SWI/SNF Inactivation in Lung Adenocarcinoma Cell Models. Cancers, 2020, 12, 3712.	1.7	6
12	LncRNA-mRNA Co-Expression Analysis Identifies AL133346.1/CCN2 as Biomarkers in Pediatric B-Cell Acute Lymphoblastic Leukemia. Cancers, 2020, 12, 3803.	1.7	7
13	Frequent mutations in the amino-terminal domain of BCL7A impair its tumor suppressor role in DLBCL. Leukemia, 2020, 34, 2722-2735.	3.3	24
14	The value of lncRNAFENDRRandFOXF1as a prognostic factor for survival of lung adenocarcinoma. Oncotarget, 2020, 11, 1172-1185.	0.8	12
15	MA17.06 Plakophilin 1 Enhances MYC Expression, Promoting Squamous Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, S319.	0.5	O
16	P1.03-20 Exploring Driver Mutations in Non-Coding RNAs in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2019, 14, S425.	0.5	0
17	Expression of the long non-coding RNA TCL6 is associated with clinical outcome in pediatric B-cell acute lymphoblastic leukemia. Blood Cancer Journal, 2019, 9, 93.	2.8	20
18	EP1.14-36 Suicide Gene Therapy Directed by MicroRNA Activity. Journal of Thoracic Oncology, 2019, 14, S1046.	0.5	0

#	Article	IF	Citations
19	Long Noncoding RNAs as Cancer Biomarkers. , 2018, , 95-114.		3
20	BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines. Clinical and Translational Oncology, 2017, 19, 1010-1017.	1.2	11
21	P2.02-010 Oncogenic Role of PKP1 in Non-Small-Cell Lung Cancer Journal of Thoracic Oncology, 2017, 12, S2101-S2102.	0.5	O
22	Preoperative chemoradiotherapy for rectal cancer: the sensitizer role of the association between miR-375 and c-Myc. Oncotarget, 2017, 8, 82294-82302.	0.8	8
23	The oleanolic acid derivative, 3-O-succinyl-28-O-benzyl oleanolate, induces apoptosis in B16–F10 melanoma cells via the mitochondrial apoptotic pathway. RSC Advances, 2016, 6, 93590-93601.	1.7	23
24	Target molecules in 3T3-L1 adipocytes differentiation are regulated by maslinic acid, a natural triterpene from Olea europaea. Phytomedicine, 2016, 23, 1301-1311.	2.3	27
25	Maslinic Acid, a Natural Triterpene, Induces a Death Receptor-Mediated Apoptotic Mechanism in Caco-2 p53-Deficient Colon Adenocarcinoma Cells. PLoS ONE, 2016, 11, e0146178.	1.1	43
26	Abstract 5052: Pro-oncogenic role of desmosomal plaque-related proteins in non-small cell lung cancer (NSCLC). , 2016, , .		0
27	Abstract 4479: Unveiling the relationship between the SWI/SNF chromatin remodeling complex and noncoding RNAs. , 2016, , .		O
28	Maslinic Acid, a Triterpene from Olive, Affects the Antioxidant and Mitochondrial Status of B16F10 Melanoma Cells Grown under Stressful Conditions. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-11.	0.5	33
29	Expression inactivation of SMARCA4 by microRNAs in lung tumors. Human Molecular Genetics, 2015, 24, 1400-1409.	1.4	26
30	Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives. Current Organic Chemistry, 2015, 19, 919-947.	0.9	53
31	SWI/SNF proteins as targets in cancer therapy. Journal of Hematology and Oncology, 2014, 7, 81.	6.9	17
32	Wiping DNA Methylation: Wip1 Regulates Genomic Fluidity on Cancer. Cancer Cell, 2013, 24, 405-407.	7.7	2
33	Antitumour activity on extrinsic apoptotic targets of the triterpenoid maslinic acid in p53-deficient Caco-2 adenocarcinoma cells. Biochimie, 2013, 95, 2157-2167.	1.3	37
34	Maslinic acid, a triterpenic anti-tumoural agent, interferes with cytoskeleton protein expression in HT29 human colon-cancer cells. Journal of Proteomics, 2013, 83, 15-25.	1.2	64
35	Microarray Profiling of Mononuclear Peripheral Blood Cells Identifies Novel Candidate Genes Related to Chemoradiation Response in Rectal Cancer. PLoS ONE, 2013, 8, e74034.	1.1	10
36	FGF Regulates TGF-Î <sup>2</sup> Signaling and Endothelial-to-Mesenchymal Transition via Control of let-7 miRNA Expression. Cell Reports, 2012, 2, 1684-1696.	2.9	265

#	Article	IF	CITATIONS
37	SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a,) Tj ETQq1	1 0,784314	rgBT /Over
38	Gene amplification of the transcription factor DP1 and <i>CTNND1</i> in human lung cancer. Journal of Pathology, 2010, 222, 89-98.	2.1	33
39	Regression of murine lung tumors by the let-7 microRNA. Oncogene, 2010, 29, 1580-1587.	2.6	465
40	OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature, 2010, 467, 86-90.	13.7	877
41	The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancerâ€. Human Molecular Genetics, 2009, 18, 1343-1352.	1.4	99
42	Inhibiting microRNA function in vivo. Nature Methods, 2009, 6, 37-38.	9.0	31
43	Expression signatures in lung cancer reveal a profile for <i>EGFR</i> â€mutant tumours and identify selective <i>PIK3CA</i> overexpression by gene amplification. Journal of Pathology, 2008, 214, 347-356.	2.1	92
44	Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Human Mutation, 2008, 29, 617-622.	1.1	226
45	Involvement of the chromatin-remodeling factor BRG1/SMARCA4 in human cancer. Epigenetics, 2008, 3, 64-68.	1.3	92
46	MicroRNAs and cancer: An overview. Cell Cycle, 2008, 7, 2485-2492.	1.3	325
47	Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene, 2007, 26, 1616-1625.	2.6	130
48	DNA-Repair Gene Polymorphisms Predict Favorable Clinical Outcome Among Patients With Advanced Squamous Cell Carcinoma of the Head and Neck Treated With Cisplatin-Based Induction Chemotherapy. Journal of Clinical Oncology, 2006, 24, 4333-4339.	0.8	132
49	Transcriptional targets of the chromatin-remodelling factor SMARCA4/BRG1 in lung cancer cells. Human Molecular Genetics, 2005, 14, 973-982.	1.4	55
50	Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene, 2004, 23, 4037-4040.	2.6	111
51	Distinctive gene expression of human lung adenocarcinomas carrying LKB1 mutations. Oncogene, 2004, 23, 5084-5091.	2.6	61
52	Genetic and Epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors. Genes Chromosomes and Cancer, 2004, 41, 170-177.	1.5	103